Wyeth-Ayerst Low-Dose Premarin Filings Slated For 2000
Wyeth-Ayerst is planning to file for FDA approval of lower dose formulations of its conjugated estrogen product Premarin by the end of the year.
Wyeth-Ayerst is planning to file for FDA approval of lower dose formulations of its conjugated estrogen product Premarin by the end of the year.